OncoPharm cover image

Tale from the Crypt: Belantamab Mafodotin

OncoPharm

00:00

DREAM7 efficacy and FDA approval subgroup

John Bizarro reviews overall and subgroup PFS and OS benefits, noting the stronger effect in patients with ≥2 prior lines.

Play episode from 05:21
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app